Lite Strategy Stock (NASDAQ:LITS)

Ownership Financials Chart

Previous Close

$0.97

52W Range

$0.69 - $9.00

50D Avg

$1.01

200D Avg

$1.45

Market Cap

$32.34M

Avg Vol (3M)

$395.04K

Beta

0.04

Div Yield

LITS Company Profile

Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.

Industry

Asset Management - Cryptocurrency

Sector

Financial Services

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Dec 18, 2003

Website

LITS Performance

LITS Financial Summary

	Jun 25	Jun 24	Jun 23
Revenue	-	$65.30M	$48.82M
Operating Income	$-17.45M	$14.54M	$-36.76M
Net Income	$-15.95M	$17.78M	$-31.84M
EBITDA	$-17.09M	$25.82M	$-36.38M
Basic EPS	$-2.39	$2.67	$-4.78
Diluted EPS	$-2.39	$2.67	$-4.78

Fiscal year ends in Jun 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 23Sep 26, 23 | 5:00 PM

Q4 22Sep 08, 22 | 5:00 PM

Q4 21Sep 02, 21 | 5:00 PM

Peer Comparison

Ticker	Company
TCRX	TScan Therapeutics, Inc.
IOBT	IO Biotech, Inc.
PMVP	PMV Pharmaceuticals, Inc.
NTRB	Nutriband Inc.
HOWL	Werewolf Therapeutics, Inc.
XBIT	XBiotech Inc.
ACRV	Acrivon Therapeutics, Inc. Common Stock
IMUX	Immunic, Inc.
ACET	Adicet Bio, Inc.
RLMD	Relmada Therapeutics, Inc.